Product pipeline

We have a broad and differentiated clinical pipeline of multiple product candidates, each for multiple indications. Our focus is on clinically validated targets and biomarkers, and we believe that our proprietary clinical programs are well-suited for a precision-medicine approach. Our pipeline also includes two partnered clinical-stage programs.

Proprietary Programs

Receptor tyrosine kinase programs
Phase 1
Phase 2
Phase 3
Metastatic Colorectal Cancer, 3rd/4th line
Advanced Glioblastoma
Epithelial cancers
MET-amplified solid tumors

Partnered Programs

Immuno-oncology programs
Phase 1
Phase 2
Phase 3
Solid tumors or lymphomas

Infectious disease programs
Staphylococcus aureus bacteremia

Our focus

We target some of the largest epithelial cancer indications, such as colorectal, lung, brain, breast, pancreatic and head and neck cancers, with the potential to expand into other indications and earlier lines of treatment.

The two partnered clinical-stage programs are an immuno-oncology program of six targets being developed in collaboration with Shire, one of which – a PD-1 antagonist – is in Phase 1 development, and a program directed to Staphylococcus aureus bacteremia, which is in Phase 1b development by Genentech.

In addition to our clinical trials, we maintain extensive proprietary and partnered discovery and preclinical activities to continue to realize the potential of our mAb mixture platform, and we anticipate to file additional INDs in 2018.

What are antibodies?

Antibodies are Y-shaped proteins produced by specialized cells of the body’s immune system. Antibodies can identify and bind disease-specific antigens found on bacteria, viruses, and cancer cells. Once attached to the antigen, antibodies can recruit other parts of the immune system to help neutralize the cells containing the antigen. The place on the antigen where the antibody binds is called an epitope. Researchers can design antibodies to target a certain antigen. Antibodies can be made in large amounts known as monoclonal antibodies (mAbs). Monoclonal antibodies are a well-established drug class today used to treat many diseases, including cancer.

Immuno-oncology is the study and development of immuno-therapies that use certain parts of a person’s immune system to fight cancer. Immunotherapies target cancer cells that have found ways to use checkpoint molecules to avoid being attacked by the immune system, allowing the cancer to grow.
Read more
Receptor tyrosine kinases
RTKs are a large family of cell-surface transmembrane receptors. RTKs play a crucial role in regulating a range of cellular functions, including growth, proliferation, differentiation, and survival. Their activity is normally tightly controlled and regulated by the body. Deregulated RTK activation and amplification is frequently seen in human cancers.
Read more
Read more about our mAb mixtures